Fig. 1
The TRIM22 expression in human SKCM tissues and its correlation with clinical characteristics. (A) Analysis of TRIM22 gene expression at the RNA level across various cancer types, providing insights into the transcriptomic landscape (TIMER2.0). ***p < 0.0001. (B) TRIM22 mRNA expressions in GSE98394 dataset of the GEO database. Mann–Whitney U test: p = 2.29 × 10−6. (C) TNMplot data for the expression of TRIM22 gene in skin tumors (n = 253), normal (n = 174), and metastatic tissue (n = 76). Kruskal–Wallis test: p = 1.13 × 10−5. (D) Correlation between the expression of TRIM22 and tumor stage in SKCM patients (GEPIA2). (E) Representative IHC micrographs of TRIM22 in skin samples and melanoma from the HPA database. Not Otherwise Specified (NOS). Scale bar, 200 μm. (F) Representative IHC micrographs of TRIM22 in collected clinical samples of melanoma samples. Quantification of the integrated optical density (IOD) is presented in the corresponding graph. N = 4 in each group. Scale bar, 50 μm. Data were shown as Mean ± SD. The standard deviations of independent experiments were represented by error bars. One-way ANOVA. ****p < 0.0001.
